# Diabetes Research Hub — Monitor Report
**Run date:** 2026-07-05 (automated)
**Previous report:** monitor_report_2026-07-04.md
**Comparison window:** 2026-07-04 → 2026-07-05 snapshots

---

## Bottom line
Another quiet local day: **zero clinical-trial changes** (0 new / 0 removed / 0 status / 0 results) and normal PubMed churn (**17 in / 14 out**) since yesterday. Two new **cross-domain** papers surfaced, both in the microbiome cluster — low strategic value. The only genuinely notable literature movement is the **CagriSema REIMAGINE 1/2/3 Phase 3 trio** (Lancet-tier) now indexed in our PubMed mirror, and a **Novo Nordisk insulin-switch trial (NCT06340854) posted results 2026-07-02**. Web check found **no breaking news in the last 7 days** — the "first cell therapy" headline circulating is Lantidra (2023), not new; zimislecel is still pre-approval, consistent with our snapshot showing Vertex trials RECRUITING. All five core files regenerated today (02:05–02:18). **No action required beyond optional tracker updates.**

---

## File System Status
All five monitored outputs present and current (generated 2026-07-05):

| File | Size | Generated |
|------|------|-----------|
| hub_monitor_report.md | 6.4 KB | 02:18 |
| clinical_trials_latest.json | 566 KB | 02:05 |
| pubmed_recent_latest.json | 121 KB | 02:06 |
| literature_gap_data.json | 124 KB | 02:18 |
| literature_gap_report.md | 4.1 KB | 02:18 |

Hub census: **1,011 files tracked; 4 new, 52 modified, 0 removed** since prior scan. The 4 new files are today's dated snapshots + yesterday's monitor report + an iterate run report — expected. The 52 modified include a full Dashboards rebuild (2026-07-04 03:08) — routine regeneration, not content-driven change.

**Staleness flag (from hub_monitor.py):** 779 result files older than 14 days. This is the historical snapshot archive (daily since 2026-03-15) plus the paper library — expected, not a problem. [Certain]

---

## Clinical Trial Changes
**Snapshot diff 2026-07-04 → 2026-07-05: 0 new, 0 removed, 0 status changes, 0 new results.** Nothing moved on the local mirror in 24h. [Certain — hub_monitor.py automated diff]

Standing totals (**839 trials**): T1D Cure & Cell Therapy 152 · T1D Immunotherapy & Prevention 74 · T2D Novel Therapies (Ph2-3) 147 · Diabetes Technology 230 · Recently Completed w/ Results 310.

**Phase 3 RECRUITING count: 48.** Key watched-sponsor Phase 3 trials, current status [Certain — clinical_trials_latest.json]:

| NCT | Sponsor | Therapy / Focus | Status |
|-----|---------|-----------------|--------|
| NCT06832410 | Vertex | VX-880 (zimislecel), T1D + kidney tx | RECRUITING |
| NCT04786262 | Vertex | VX-880 (zimislecel), T1D | RECRUITING |
| NCT07222332 | Eli Lilly | Baricitinib — BARICADE-PRESERVE (new-onset T1D) | RECRUITING |
| NCT07222137 | Eli Lilly | Baricitinib — delay Stage 3 T1D at-risk | RECRUITING |
| NCT07088068 | Sanofi | Teplizumab vs placebo, Stage 3 T1D (1–25 yr) | RECRUITING |
| NCT06334133 | vTv Therapeutics | Cadisegliatin (glucokinase activator), T1D adjunct | RECRUITING |
| NCT05929079 / NCT06260722 | Eli Lilly | Retatrutide, T2D | ACTIVE_NOT_RECRUITING |
| NCT06534411 | Novo Nordisk | CagriSema, T2D | ACTIVE_NOT_RECRUITING |

**Recently posted results worth a glance** (trial mirror) [Certain]:
- **NCT06340854** (Novo Nordisk) — switching from daily basal insulin, results posted **2026-07-02**.
- **NCT06010004** (Eli Lilly) — Orforglipron long-term safety, posted 2026-06-30 (flagged last run).
- NCT01897688 (Northwestern) — Phase 3 islet transplantation, posted 2026-06-18 — relevant to our Islet Transplant Tier interest.

---

## PubMed Highlights
Mirror holds **155 unique papers** over a 30-day lookback across 16 domains. Daily churn: **17 new, 14 dropped**. [Certain — hub_monitor.py diff]

**Cross-domain new papers (highest-priority signal), 2 today:**
- **[42400043]** Multi-omics profiles of sex hormone-binding globulin & subclinical atherosclerosis — *Diabetes Microbiome × Diabetes Multi-Omics*
- **[42401402]** The Microbiome-Gut-Gonad Axis: microbial metabolites & reproductive physiology — *Diabetes Biomarker × Diabetes Microbiome*

Both sit in the microbiome cluster and are tangential to our Tier 1 priorities (islet/beta-cell, immunomodulation). Low action value. [Likely]

**Key-therapy tracker (papers this cycle):** orforglipron 5 · retatrutide 5 · teplizumab 5 · CagriSema 5 · baricitinib 4 · icodec 4 · **zimislecel 0**. [Certain — therapy_hits]

**Most notable literature (new since yesterday):**
- **CagriSema REIMAGINE 1 / 2 / 3** — [42251860], [42251859], [42251856] — three Phase 3a T2D readouts (placebo, semaglutide/cagrilintide comparator, and basal-insulin add-on). This is the substantive scientific event of the cycle. **Evidence level: Level 1b (individual RCT).** [Certain]
- [42338042] Orforglipron hepatic-safety pooled Phase 3 analysis; [42363271] orforglipron obesity+T2D meta-analysis.
- [42267680] Early teplizumab response via CGM — methodologically relevant to our CGM × immunotherapy interest.

---

## Gap Analysis Summary
Regenerated today; 30 domains, 435 pairs. **Top 5 under-researched intersections** (gap score 100.0, all HIGH) [Certain — literature_gap_report.md]:

| Rank | Intersection | Joint / Expected Pubs |
|------|--------------|-----------------------|
| 1 | Beta Cell Regen × Health Equity | 0 / 1,697 |
| 2 | Insulin Resistance × Islet Transplant | 1 / 2,216 |
| 3 | Insulin Resistance × Closed Loop/AP | 3 / 6,126 |
| 4 | Islet Transplant × GWAS/Polygenic | 0 / 1,144 |
| 5 | Islet Transplant × Personalized Nutrition | 0 / 402 |

**Doctrine alignment:** Ranks 1, 2, 4, 5 all touch **Beta Cell Regeneration** and **Islet Transplant** — both Tier 1 contribution areas. The matrix is stable vs. prior runs (these intersections have persisted at gap 100 for weeks), which is itself the finding: these are durable white-space, not noise. Caveat unchanged — a gap score of 100 can mean genuine white space *or* terminology mismatch; requires expert cross-check before any claim. [Likely]

---

## Breaking News (web check, last 7 days)
**Nothing new this week.** [Likely — WebSearch 2026-07-05]

Context to avoid re-flagging stale items: FDA generic dapagliflozin (Apr 7), Langlara insulin glargine biosimilar (Apr 29), Ranluspec ranibizumab biosimilar (Jun 5), Portal Pump Breakthrough Device (Feb 17), and the Tzield/teplizumab Stage 3 pediatric label expansion — all previously logged, none within the last 7 days. The "FDA approves first cellular therapy for T1D" headline resolves to **Lantidra (2023)**, not a new action. **Zimislecel remains pre-approval** (Vertex submission expected 2026), consistent with our mirror showing both Vertex Phase 3 trials still RECRUITING. [Certain]

---

## Recommended Actions
1. **Optional:** Log **NCT06340854** (Novo, results posted 2026-07-02) in `Diabetes_Research_Tracker.xlsx` if tracking basal-insulin switch data.
2. **Consider a focused pull** of the **CagriSema REIMAGINE 1/2/3** trio into the paper library — the cycle's only Level-1b evidence event.
3. **No re-runs needed** — all five data files regenerated today (<1 day old).
4. **Housekeeping (carryover):** confirm `Dashboards/Paper_Library.html` is writing correctly; it was flagged 0 bytes in a prior run.
5. **No new claims warranted** this cycle — trial mirror static, cross-domain signal is off-thesis (microbiome), gap matrix unchanged.

---
*Generated by diabetes-hub-monitor (automated review run) — 2026-07-05. This run READ only; no hub files modified.*
